Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours
It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.
You may also be interested in...
Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities
The number of US biopharma IPOs during the first 11 months of 2016 – 29 companies went public – is less than half of the 2015 total of 62, but stock performance has improved as investors focus on quality.
Efficiency Bows To Scrutiny: '90s Drug Development Timelines Have Doubled
The time it takes to get a new drug candidate through clinical trials and onto the market has almost doubled since the late 1990s – but timescales for discovering new drug candidates haven't changed over the past 15 years.
Case Studies: How Three Public Companies Financed R&D In A Tough Market
The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.